Stifel Nicolaus Begins Coverage on Aimmune Therapeutics (AIMT)

Share on StockTwits

Stifel Nicolaus initiated coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Thursday, The Fly reports. The brokerage issued a hold rating and a $33.00 price objective on the biotechnology company’s stock.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Aimmune Therapeutics from a hold rating to a sell rating in a research report on Tuesday, August 28th. Credit Suisse Group set a $40.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research report on Monday, August 13th. Piper Jaffray Companies started coverage on shares of Aimmune Therapeutics in a research report on Friday, May 18th. They issued an overweight rating and a $30.01 target price on the stock. Finally, Wedbush reissued an outperform rating and issued a $72.00 target price on shares of Aimmune Therapeutics in a research report on Wednesday, May 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $50.90.

Aimmune Therapeutics stock opened at $27.99 on Thursday. The company has a market capitalization of $1.70 billion, a PE ratio of -10.72 and a beta of -0.28. Aimmune Therapeutics has a fifty-two week low of $22.85 and a fifty-two week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.05). research analysts predict that Aimmune Therapeutics will post -3.63 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in AIMT. Tiverton Asset Management LLC purchased a new position in Aimmune Therapeutics during the second quarter valued at approximately $145,000. Ardsley Advisory Partners purchased a new position in Aimmune Therapeutics during the second quarter valued at approximately $202,000. Xact Kapitalforvaltning AB purchased a new position in Aimmune Therapeutics during the first quarter valued at approximately $207,000. WINTON GROUP Ltd purchased a new position in Aimmune Therapeutics during the first quarter valued at approximately $262,000. Finally, Fred Alger Management Inc. purchased a new position in Aimmune Therapeutics during the second quarter valued at approximately $269,000. 78.16% of the stock is currently owned by hedge funds and other institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

See Also: What is the Dow Jones Industrial Average (DJIA)?

The Fly

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing Ellie Mae  & Coupa Software
Comparing Ellie Mae & Coupa Software
Chemed Co.  Receives Consensus Recommendation of “Buy” from Analysts
Chemed Co. Receives Consensus Recommendation of “Buy” from Analysts
QuinStreet Inc  Receives Average Rating of “Buy” from Brokerages
QuinStreet Inc Receives Average Rating of “Buy” from Brokerages
eGain Corp  Given Average Rating of “Buy” by Analysts
eGain Corp Given Average Rating of “Buy” by Analysts
FLIR Systems  Downgraded to Hold at BidaskClub
FLIR Systems Downgraded to Hold at BidaskClub
ICU Medical  Downgraded by BidaskClub
ICU Medical Downgraded by BidaskClub


Leave a Reply

 
© 2006-2018 Zolmax.